Polyplus

Sartorius, through its French listed subgroup Sartorius Stedim Biotech, successfully acquired Polyplus in July 2023. The French company is a leading provider of innovative technologies for cell and gene therapies. Transfection reagents developed and produced by Polyplus are key components in the manufacture of viral vectors.